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bSpaarne Hospital, Hoofddorp, The Netherlands1. Introduction workshop, inadequate agreement was reached regardingTwenty researchers in the ﬁeld of neuromuscular
disorders from eight diﬀerent countries (USA, Canada,
Spain, Italy, France, Belgium, The Netherlands, UK), and
a patient representative of the GBS/CIDP Foundation
International (Glennys Sanders) participated in the 196th
ENMC international workshop in Naarden, The
Netherlands from February 8th to 10th 2013 to discuss the
results of the peripheral neuropathy outcome measurement
standardisation (PeriNomS) study and to strive for
consensus on a speciﬁc core set of outcome measures to be
used in future clinical trials and follow-up studies in
patients with Guillain–Barre´ syndrome (GBS), chronic
inﬂammatory demyelinating polyradiculoneuropathy
(CIDP), monoclonal gammopathy of undetermined
signiﬁcance related polyneuropathy (MGUSP), and
multifocal motor neuropathy (MMN).
In 2004, the ﬁrst workshop on outcome measures in
peripheral neuropathies was held on the auspice of the
European Neuromuscular Centre (ENMC). At this 131st0960-8966/$ - see front matter  2013 Elsevier B.V. All rights reserved.
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I.N. van Schaik, the Netherlands; M. de Visser, the Netherlands.which outcome measures should be used at the
impairment and activity and participation levels in future
trials involving patients with inﬂammatory neuropathies,
like GBS, CIDP, MGUSP (IgM paraproteinemia with
positive anti-myelin associated glycoprotein antibodies),
and MMN [1]. Recommendations were provided to
perform a comparison study between outcome measures
that formed the basis of the current workshop. Based on
these recommendations, the PeriNomS study was
conducted between 2007 and 2012.2. Background
2.1. PeriNomS study: background and recruitment ﬁndings
The PeriNomS study (2 years of preparation, 5 years of
data collection; kick-oﬀ 2007, PNS, Utah, USA; dbase
closed 31st December 2012) is an international
collaborative eﬀort of 26 neuromuscular centres with
special interest in inﬂammatory neuropathies. Through
comparative responsiveness studies, the most responsive
measures were selected at the various levels of interest of
assessing outcome. The study consisted of two parts: the
cross-sectional part and the longitudinal part (Fig. 1). The
cross-sectional part mainly focused on examining validity
and reliability in 122 recruited patients (GBS: 30, CIDP:
30, MGUSP: 20, MMN: 22, inﬂammatory small ﬁbre
neuropathy (SFN): 20) with a clinical stable condition with
residual symptoms and signs. These patients were
examined twice (interval 2–4 weeks) by two well trained
and independent observers to obtain inter-/intra-observer
reliability scores. Patient-reported outcomes were assessed
twice by patients in the same way, without having access to
cross-sectional
validity & reliability
n= 122
longitudinal
responsiveness
n = 163
The
Netherlands
MUMC
UMCU
Erasmus MC
comparative study, duration 5 years
26 centres
PeriNomS –design
Fig. 1. The design of the cross-sectional and the longitudinal part of the
PeriNomS study.
E.K. Vanhoutte et al. / Neuromuscular Disorders 23 (2013) 924–933 925the previous scores. The longitudinal studies were performed
worldwide (at the collaborating centres) and the data were
centrally collected (Erasmus MC and Maastricht UMC,
The Netherlands), and were used to determine
comparative responsiveness scores between equally valid
and reliable pre-selected outcome measures in
inﬂammatory neuropathies. A total of 163 newly
diagnosed patients (GBS: 55, CIDP; 59, MGUSP: 23 of
which 19 were IgM anti-myelin associated glycoprotein
positive, MMN: 26) were enrolled and examined during a
one-year period (GBS and CIDP: examined at T0, T1, T3,
T6, and T12 months; MGUSP and MMN: examined at
T0, T3, and T12 months). Basic characteristics of these
patients were presented including treatment regimens if
reported. The workshop mainly focused on the cross-
sectional validity and reliability and longitudinal
responsiveness results by comparing the (modiﬁed)
Medical Research Council (MRC) sum score versus
neuropathy impairment scale (NIS) motor subset, the
modiﬁed inﬂammatory neuropathy cause and treatment
(INCAT) sensory sum score versus NIS sensory subset,
the Jamar dynamometer versus the Martin Vigorimeter,
the INCAT disability 10-point scale, the overall disability
sum score (ODSS), the overall neuropathy limitations
scale (ONLS) versus the newly devised inﬂammatory
Rasch-built overall disability scale (R-ODS) [2,3].2.2. Historical background of clinical assessments in
inﬂammatory neuropathies
RichardHughes,UKreviewed the historical backgroundof
the development of outcome measures focussing on strength,
sensation and disability, relying in part on the historical essay
provided by Dyck and colleagues [4]. In 1917 Robert Lovett,
a Boston orthopaedist introduced a system for scoring
weakness by manual muscle testing, ranging from 1 being
normal to 6 paralysis [4]. In 1942 the order of scoring wasreversed by the Medical Research Council to provide a scale
for scoring strength ranging from 0 for paralysis to 5 for
normal [4]. The MRC grading system was developed to
assess peripheral nerve injuries but it has become used
throughout all kinds of neurological illnesses. It became
apparent that the MRC grades have unequal widths with
grade 4 covering a much wider range than the other grades.
The MRC sum score was developed derived adding the
scores of 6 pairs of muscles to try to represent the overall
strength of a patient. This composite measure has served
through the years as an outcome measure in numerous trials
involving patients with inﬂammatory neuropathies [5]. In
parallel, the Mayo Clinic developed what came to be called
the neuropathy impairment score with more grades of
severity for milder weakness than the MRC grading system:
muscle weakness is scored as follows: 0 = normal; 1 = 25%;
2 = 50%; 3 = 75% weak; 3.25 = movement against gravity
just possible; 3.5 = movement with gravity eliminated just
possible; 3.75 = ﬂicker; and 4 = paralysed [4]. Alternative
methods of scoring sensory impairment have been developed,
the INCAT sensory sum score (ISS) in Europe and the
neuropathy impairment sensory score (NISsens) at the Mayo
clinic [4,6]. Disability measures have been developed for
inﬂammatory neuropathies such as 7-point disability scale
for GBS and the 10-point inﬂammatory neuropathy cause
and treatment (INCAT) disability for chronic inﬂammatory
neuropathies. The latter has been further modiﬁed into the
overall disability sum score (ODSS) and ﬁnally the overall
neuropathy limitations score (ONLS) [3].
2.3. Trial design and outcome models in GBS and other
inﬂammatory neuropathies
Pieter van Doorn, The Netherlands, discussed the issues
in trial design and outcome models. For rare disorders like
inﬂammatory neuropathies, it may be important to use
advanced prognostic modelling, which enables researchers
to reduce the required sample size, hereby considerably
shortening the length of trials in these conditions. In order
to obtain comparability between trials, the use of
previously used outcome measures was proposed.
However, this statement was debated, since persistent use
of improper outcome measures may continue to jeopardise
the results in the same way as seen in the past. Proper
attention should be given to the choice of the best outcome
measure, particularly choosing outcome measures that
have been tested in terms of their clinimetric properties in
the disease of interest and fulﬁlling modern requirements
[7]. Also, time of assessment during the course of the
illness of interest is important, since the course of
inﬂammatory neuropathies may vary and with this
possible improvement in patients [8]. Possible reasons for
trials in the inﬂammatory ﬁeld being negative were
addressed highlighting the possibility of insensitive
outcome measures contributing to this. Finally, the need
for international collaboration in these rare disorders was
emphasised.
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Ingemar Merkies, The Netherlands, presented on behalf
of David R. Cornblath (USA) the traditional basic
requirements for outcome measures. Several types of data
were discussed. Outcome measures at the nominal and
ordinal level are descriptive and the collected data are
qualitative without having a numerical value. Despite this
general knowledge, we have been allocating numbers to
descriptive response categories of each item and have
been doing parametric analyses on calculated sum scores,
assuming linearity [9]. Measurements at the interval or
ratio level increase the level of precision in the assessment
of interest since the recruited data have a numerical
value. The distance between the categories is known, and
therefore meaningful calculations can be performed.
The international classiﬁcation of functioning, disability
and health (ICF) is an international framework classifying
the consequences of a health condition [10]. The ICF was
discussed addressing its domains: body functions and
structures (limitation in one of these is addressed as
impairment, e.g., paresis) and activities and participation
(capturing daily activities and social functioning, e.g.,
dressing up, fulﬁll a job). Limitations at any of these
levels may contribute to the concept of quality of life that
embraces patients’ reaction to the discrepancy between
actual and expected achievements arising as a
consequence of their illness [7].
Outcome measures should be simple, valid, reliable and
responsive [7]. The advantages and disadvantages of
traditional ‘classic test theory’ ordinal based composite
outcome measures were summarized [9]. In brief,
outcome measures in inﬂammatory neuropathies are
generally ordinal multi-items composite measures that
recruit items arbitrarily. Sum scores are generally used,
assuming that all items have equal weight, hence
assuming a ﬁxed unit and thus treating the data as if
these were at the linear level. Additionally the diﬀerences
obtained in a sum score throughout the range of the
constructed sum score have been equally treated. All
these assumptions are highly unlikely and hamper the
interpretation of the results in/between clinical trials [9].
3. Modern requirements for outcome measures
3.1. Requirements for outcome measures: modern aspects
through Rasch analyses
Catharina Faber, The Netherlands, explained the
‘modern’ clinimetric approach through the concept of the
Rasch model [11,12]. This model is based on a logical
assumption: a patient with a high ability (a term used for
any particular trait of interest; e.g., mobility, or
performing daily and social activities etcetera; in essence,
a less ill patient) will have a higher probability of
aﬃrming a particular task compared to a patient with a
lower ability (more ill patient) [11]. The Rasch methodenables researchers to transform ordinal obtained data
into an interval metric, hereby increasing the level of
precision. Both the ability of a patient and the diﬃculty
of a task, having a logarithmic relation, are placed on the
same ruler (with logits as the ﬁxed unit) [11]. Items and
patients are ordered according to the Guttman scaling
procedure. An example of ordering items in terms of
their diﬃculty and patients in terms of their ability on
the same metric was provided in lay terms. The RUMM
(Rasch unidimension measurement model) was presented
explaining through various real data examples some of its
model requirements (like ﬁt statistics, disordered
thresholds, local dependency, item bias, and proper
targeting). Emphasis was put on the need to review data
that are not fulﬁlling model expectations and if possible
to modify (“clean-up”) these to improve model ﬁtting.
3.2. ACTIVLIM, a measure of activity limitations in
children and adults with various neuromuscular disorders
Peter Van den Bergh, Belgium, discussed the
development of the ﬁrst Rasch-built measures addressing
activity limitations (ACTIVLIM) in both adults and
children with various neuromuscular disorders in order to
follow patients’ evolution over time. This measurement
fulﬁlled basic and Rasch model requirements [13]. In
addition, their experience through the years using this
outcome measure and eﬀorts to introduce its use
nationally in the 6 accredited neuromuscular reference
centres by means of a dedicated Belgian neuromuscular
Disease Registry website application were addressed. Also,
the availability of obtaining an online score for the
ACTIVLIM was shown. It was agreed upon, that the item
weights obtained with this scale diﬀered from those
obtained from the GBS, CIDP, and MGUSP speciﬁc
R-ODS [2]. The diﬀerences were explained by the diﬀerences
in cohorts of patients examined (ACTIVLIM examining
patients with all forms of neuromuscular illnesses, R-ODS
being disease speciﬁc). Finally, the construction of the
ABILHAND measure through Rasch analyses, a tool to
assess upper limb activity limitations was also discussed [14].
3.3. The concept of MCID and deﬁning a responder
Ingemar Merkies, The Netherlands, explained the
concept of MCID and deﬁning a responder. Traditional
clinical trials tend to demonstrate the eﬃcacy of a
particular intervention by looking at p-values for groups’
comparison or by comparing proportions of patients
reaching an arbitrary pre-deﬁned meaningful cut-oﬀ for an
endpoint of interest. However, all these comparisons
assume a ﬁxed standard error (SE) across the metric being
used. The concept of MCID was also addressed,
highlighting its complexity due to the various available
techniques [15]. The MCID represents a change that is
considered meaningful and worthwhile by the patient such
that they would consider repeating the intervention [16].
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Fig. 2. Demonstrating the U-shape SE pattern seen across interval/linear
outcome measures. (A) Schematic representation of the U-shape SE
pattern across an outcome measure of interest; (B) SE ﬁndings in two
Rasch-Transformed motor composite scales; (C) formula used to deﬁne
meaningful improvement being deﬁned asP1.96  SE for each individual
patient, at a chosen of 95% conﬁdence interval [18,19]. RT, Rasch
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methods were discussed [15,17]. Currently, there is no
consensus regardingwhichMCID technique should be used.
Responsiveness techniques like the eﬀect size can be
misleading when doing groups comparison of the
calculated responsiveness scores found between outcome
measures in the same population at study [18]. However,
using modern techniques like the Rasch method,
comparison at the ‘individual level of being a responder’
can be made by using the model’s provided individual
standard errors for each patient at the various assessment
time points. Outcome measures evaluated through Rasch
demonstrate a ‘U’-shape SE across the outcome measure
range being used (see Fig. 2 for an example) [18,19].
For the comparison purposes of the PeriNomS study, a
responder was deﬁned as a patient in whom the clinical
condition improved enough to fall outside the MCID
threshold boundaries of 1.96  SE for the scale at study
(see Fig. 2C) [18,19].
By using this method, responders could be determined
at the individual level in addition to groups’ comparison
(Fig. 3). For the Jamar versus Vigorimeter comparison, a
combined (1 anchored-based and 1 distribution-based
MCID technique) approach was used as previously
suggested [17].
4. Impairment measures
4.1. MRC grading system: original versus Rasch-built
modiﬁcation
Ingemar Merkies, The Netherlands, presented data on
the ordinal-based 6-point MRC grading system, showing
that the MRC did not meet Rasch model’s expectations,
despite being used over 7 decades and in various
neuromuscular clinical trials. In 1065 patients, with 7
diﬀerent neuromuscular illnesses, almost 80% of all
muscles were not properly scored by physicians, most
showing disordered thresholds. The ability to properly
discriminate between the diﬀerent response options was
hardly inﬂuenced by factors like experience of the
physician and type of illness. Using the Rasch model,
the 6-point MRC score was modiﬁed to a proposed
four-points grading system [20]. Its use is, however,
suggested only as part of Rasch-transformed composite
scores in future clinical studies, since the four response
categories are still ordinal based.transformed; MRCss, Medical Research Council sum score; NIS,
neuropathy impairment scale; SE, standard error.4.2. MRC sum score versus NIS motor subset
Els Vanhoutte, The Netherlands, presented the
equivalent validity and reliability ﬁndings in the
cross-sectional comparison of the NIS motor subset
versus the MRC sum score. Comparison between the
scales was performed after Rasch transformation (RT-)
and modifying the data as much as possible to meetmodel requirements, as important steps preceding
comparison of the ﬁndings. The signiﬁcant meaningful
improvement (SigChange) was equivalent between the
RT-MRC sumscore and the RT-NIS motor subset.
SigChange for motor scales was mainly seen in patients
with GBS (50%) and to a lesser extent in CIDP (20%).
For both scales, SigChange was hardly seen in MMN.
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Fig. 3. Explaining the use of the individually obtained SE through Rasch
to determine ‘being a responder’. From the formula described in Fig. 2C,
ﬁve subgroups of patients can be determined; a cut-oﬀ of 1.96  SE was
applied for all comparison studies as part of the PeriNomS workshop.
Since we were seeking for improvement in the PeriNomS study, all
individuals exceeding +1.96  SE were considered having a meaningful
improvement; [18,19] SE, standard error. The ﬁgure should be read from
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these patients received no active therapy.4.3. Modiﬁed INCAT sensory scale versus NIS sensory
subset
Els Vanhoutte, TheNetherlands, presented the comparison
data between the modiﬁed ISS versus the NIS sensory subset.
The ISS was modiﬁed (mISS) by incorporating in a
standardized manner the examination of light touch sense,
joint position sense, and the 2-point discrimination cut-oﬀs
that were based on recruited normative values [21].
Diﬀerences in their construction were addressed (mISS
having a proximal gradient in its assessment versus sensory
examination being only distally located in the NIS). The NIS
sensory subset and the mISS had equivalent validity and
reliability ﬁndings with a slightly better targeting of the mISS
(better ﬁtting to the patients’ location on the metric by the
mISS items’ thresholds).
Thereafter, Kenneth Gorson, US, showed that the
proportion of patients reaching the signiﬁcant change
cut-oﬀ (61.96  SE; SigChange) were higher for the
mISS compared to the NIS sensory subset. Furthermore,
SigChange was mainly seen in patients with GBS (40%)
(in CIDP only 10%). The SigChange was even less in
patients with MGUSP (<10%).4.4. Jamar versus Vigorimeter
Els Vanhoutte, The Netherlands, showed that there
were no diﬀerences in validity and reliability aspects
between the Martin Vigorimeter and the Jamar.
However, in all illnesses, most patients preferred the
Vigorimeter. Since both instruments are at the ratio level,
a combined MCID anchor-based (SF-36, question
number 2) and a MCID distribution-based approach
(uniﬁed rule of ½  SD) were adopted for comparison
purposes [17]. In essence, a patient was labelled as being
a responder, if both MCID cut-oﬀs were exceeded.
Signiﬁcant meaningful grip strength changes were
equivalent between the two instruments. The longitudinal
ﬁndings validated the suggested “many faces” of MCID,
since the magnitude of the results varied depending on
the MCID technique used [15]. Meaningful changes were
mainly seen in patients with GBS (up to 81% with the
Vigorimeter and 84% with the Jamar at 1 year follow-
up), followed by the patients with CIDP (40% for both
instruments), SigChange was relatively low in MMN
(Vigorimeter: 23.5%, Jamar 12.5% at 1 year follow-up)
and hardly seen in MGUSP (6.7% versus 13.3%,
respectively). The preference of patients for the Martin
Vigorimeter was validated in the longitudinal group of
patients throughout all illnesses.4.5. Is there a place for skin biopsy as an outcome in
inﬂammatory neuropathies?
Giuseppe Lauria, Italy, discussed the state of the art in
skin biopsies, focusing on facts and pitfalls. Skin biopsy
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may be used in follow-up studies, as has been shown in
some experimental studies. For clinical use, age and
gender-adjusted normative data for the IENF density at
the distal leg are available [22]. IENF density at the distal
leg was reduced in GBS, CIDP and anti-MAG
inﬂammatory neuropathies [23]. Furthermore, the IENF
density at the distal leg correlated with early pain in GBS
[23]. Several questions remain to be answered such as
right-to-left variability, intra- and inter-individual
variability over time and normal values for IENF density
at proximal sites.
Dermal nerves may also reveal important information
[24], particularly in inﬂammatory neuropathies like GBS,
CIDP, and MGUSP. However, the value of
morphological changes, length measurement, myelin
disruption, Ig, cell and complement depositions in the
skin need further validation. In addition, the recruitment
of normative values for dermal nerve assessment and
determining potential diﬀerences in counting between
laboratories were discussed. A place for skin biopsy
ﬁndings as secondary outcome or exploratory outcome
was proposed.
4.6. Is there a place for EMG as an outcome in inﬂammatory
neuropathies?
Vera Bril, Canada, discussed nerve conduction studies
(NCS) in inﬂammatory neuropathies mainly focusing on
the results of the ICE trial [25]. In addition, the value of
having a central core lab for quality control and
guidance purposes of NCS in multi-centre trials was
discussed. NCS are necessary for diagnosis, and are
considered objective measures that reﬂect clinical change
and provide supportive evidence for positive therapeutic
results. The use of NCS as an endpoint is also proposed
by the FDA. NCS as a secondary outcome measure was
proposed.
4.7. Pathophysiology of CIDP
Ivo van Schaik, The Netherlands, questioned whether
we should re-focus on unravelling pathophysiological
mechanisms underpinning inﬂammatory neuropathies. A
historical overview of pathophysiological studies
including possible biomarkers in inﬂammatory
neuropathies was discussed. Understanding all these may
contribute to determine future trial strategies and/or
directions for treatment regimens.
Biomarkers could be useful to deﬁne subgroups with
diﬀerent pathogenic mechanisms and with diﬀerent
responses to treatment. Diﬀerent possible antibodies and
genetic factors were discussed, particularly highlighting
the approach shown recently in a group of patients with
anti-contactin antibodies [26]. The need for CIDP (and
other inﬂammatory neuropathies) registry and
biobanking was stated.5. Activity and participation
5.1. Disability measures in inﬂammatory neuropathy trials
Michael Lunn, UK, discussed the deﬁnition of disability
as presented by the WHO in 1980 and 2001 and then gave
an overview of the disability measures used in
inﬂammatory neuropathy trials up to 2013 [10]. The term
disability was replaced by the positive concept of
‘activities’ in the 2001 WHO deﬁnitions and is described
as ‘the nature and extent of executing a task or action by
an individual’. The clinimetric aspects of the disability
measures used in trials so far were discussed and the
advantages and disadvantages of classical test theory and
Rasch built scales were highlighted. In turn, the GBS
Disability scores, the modiﬁed Rankin score, the
functional Independence measure, the Rivermead
Mobility Index, the Guy’s originated disability scores
(GNDS, INCAT, ODSS and ONLS), the AMC linear
disability scale [27], the ALDS item bank [28], the
ACTIVLIM [13] and the R-ODS [2]) scales were
illustrated in detail. Lunn concluded that activity and
participation should be the primary outcome level in
trials in inﬂammatory neuropathies mainly because of its
meaning to patients and care-givers, and the general ease
and applicability of scales in this domain.
5.2. The R-ODS family: their construct and (dis)advantages
Els Vanhoutte, The Netherlands, presented the
development of a patient-based, linearly-weighted Rasch-
built overall disability scale (R-ODS) and the evaluation
of its clinimetric properties. The 24-item R-ODS for
GBS, CIDP and MGUSP fulﬁlled all Rasch model
expectations [2]. However, the R-ODS as it is currently
used showed item bias in 6 of the 24 (25%) items when
examining cultural diﬀerences. Cross-cultural validation is
mandatory for international use of any scale. Therefore,
re-modelling of the R-ODS should be undertaken. The
most widely used activity scale in GBS and CIDP is the
INCAT 10-points disability measure [29]. Its construct is
quite similar to the ODSS and ONLS. For comparison
purposes, the collected longitudinal data of the ONLS
was transformed through Rasch and demonstrated
improper targeting with large gaps between items, local
dependency, and misﬁt statistics for all items.
Comparison between the RT-ONLS and the R-ODS
showed a signiﬁcant higher proportion of meaningful
improvement (SigChange; cut-oﬀ P1.96  SE) in the R-
ODS when compared to INCAT-ODSS-ONLS. With
respect to the R-ODS, a higher proportion of SigChange
was seen in patients with GBS (up to 100% at 1 year of
follow-up; INCAT-ONLS: 80%) compared to CIDP
(45% at 1 year follow-up; INCAT-ONLS 28%). The
SigChange was poor in patients with MGUSP (at
3 months 20%; most probably determined by the few
patients that received therapy; at 1 year 6%).
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Ingemar Merkies, The Netherlands, demonstrated the
composition of the R-ODS speciﬁcally for MMN
including its validation, reliability and responsiveness
ﬁndings using Rasch. A relatively low SigChange was
seen in the R-ODS for MMN (only 20% being a
responder at 1 year; cut-oﬀ 1.96  SE). This was most
probably explained by most patients not being naive
treated patients. Based on these ﬁndings the following
suggestions were made for evaluating patients with MMN:
 Perhaps examining ‘being a responder’ should be
performed using a much lower cut-oﬀ, e.g. at 1  SE
or the deﬁnition of being a responder should be
revisited, not only including the subgroup of
signiﬁcant improvement, but also non-signiﬁcant
improvement, and stability (i.e. responders are those
patients that do not deteriorate).
 MMN (and MGUSP) should be examined for a longer
period over time due to their indolent course to
capture relevant changes.
The group discussed that in naive MMN patients
signiﬁcant improvement should be sought for. In addition,
in those patients who are receiving maintenance therapy,
being a responder could be applied in the broader
deﬁnition as presented above. A self-evaluation scale (SES)
in MMN, based on the Canadian occupational
performance measure (COPM) [30] demonstrated 20%
SigChange (1 year follow-up; cut-oﬀ 1.96  SE). However,
since the items vary per patient, no adaptations to Rasch
model could be achieved using this outcome measure.
6. Quality of life
6.1. Patients perspective
Glennys Sanders, UK, urged for the recognition of the
importance of patients’ experiences, expectations and
emotions. Physicians should take factors like motivation,
fatigue, pain and acceptance into account, since these
factors can cause depression and aﬀect concentration and
conﬁdence to focus on the challenges of their recovery.
Furthermore these factors contribute signiﬁcantly to
disability and quality of life reduction. The importance of
a positive and supportive/encouraging approach towards
patients with inﬂammatory neuropathies was stressed.
Attention for the impact of those receiving respiratory
ventilation as well as for those being not able to smile were
addressed. The group acknowledged that more attention
for these aspects should be the focus of future studies in
these conditions. Patients need an ability to express their
anger, frustration and fears both for the present and
future. Therefore, Sanders emphasised that all patients
should be guided to relevant Support Groups to enable
them to share knowledge, experiences and emotions.7. Recommendations
After taking all the presented results into account, the
group aimed to get consensus on a speciﬁc core set of
outcome measures to be used in all future trials in
patients with GBS, CIDP, MGUSP, and MMN separately.
Table 1 provides an overview of the recommendations.
7.1. GBS
The primary outcome inGBS in future trials should be at the
activity and participation level measured by the inﬂammatory
R-ODS [2], since it has demonstrated signiﬁcantly higher
responsiveness compared to the INCAT–ONLS.
7.1.1. Minimal core set for future GBS studies
The minimum core set should include:
 At the impairment level: the Martin Vigorimeter, the
Rasch-transformed-mISS, being ventilated (Y/N)
and the duration of respiratory ventilation.
 At the activity and participation level: the R-ODS
and the GBS disability scale. The latter was
suggested for historical purposes.7.1.2. Recommendations in GBS
It was recommended that future trials should also
include the RT-FSS [31], the RT-MRC sum score, and
the original MRC sum score, although no consensus was
reached on this.
7.1.3. Future needs in GBS
Pain should be further evaluated in terms of its
underlying pathophysiological mechanism as well as in
terms of evaluating proper therapy. Also, measuring
strength needs further exploration, since there was no
consensus how, and if, strength should be measured; the
possibility of including a muscle dynamometer and the
RT-MRC sum score were discussed. The R-ODS could
be further improved, by cross-cultural modiﬁcation. At
the quality of life level, a Rasch-transformed outcome
measure based on the future ﬁndings of the PeriNomS
study should be included.
7.2. CIDP
The primary outcome in CIDP in future trials should be
at the activity and participation level measured by the R-
ODS [2], since it has demonstrated signiﬁcantly higher
responsiveness compared to the INCAT-ONLS.
7.2.1. Minimum core set for future CIDP studies
The minimum core set should include:
 At the impairment level, the Martin Vigorimeter, the
RT-mISS, and a ‘manual muscle testing’ procedure,
not otherwise deﬁned.
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and the original INCAT disability score.
 At the quality of life level, the 5-points patient global
impression of change (PGIC) [32] and SF-36 [33]
should be used until the data of the PeriNomS study
regarding quality of lifemeasures are further analysed.7.2.2. Recommendations in CIDP
It was recommended to use the RT-FSS and to include
pain measurements such as the 11-point Pain-Intensity
Numerical Rating Scale (PI-NRS) [32].
7.2.3. Future needs in CIDP
The RT-MRC sum score needs further development,
and should possibly include additional muscles. The
criteria for measuring pain should be examined. A
walking test (2 or 6 min) could be considered. The
R-ODS could be further improved, by cross-cultural
modiﬁcation. At the quality of life level, a
Rasch-transformed outcome measure based on the future
ﬁndings of the PeriNomS study should be included.
7.3. MMN
The primary outcome in MMN in future trials should be
at the activity and participation level measured by the
disease speciﬁc R-ODS [34].Table 1
Overview of the minimum core set, recommendations, and future needs.
GBS CIDP
Minimal core set
Impairment level Martin Vigorimeter Martin Vigorime
RT-mISS RT-mISS
Being ventilated (Y/N) ‘Manual muscle t
Duration of ventilation
Activity and participation
level
R-ODS R-ODS
GBS disability scale Original INCAT
score
Quality of life level – 5-PGIC
SF-36
Recommendations
Impairment level RT-MRCss 11-PI-NRS
Original MRCss RT-FSS
RT-FSS
Activity and participation
level
–
Quality of life level –
Future needs
Impairment level Pain RT-MRCss
Muscle dynamometer/RT-
MRCss
Pain
Walking test
Activity and participation
level
Cross-cultural R-ODS Cross-cultural R-
Quality of life level RT-QoL scale RT-QoL scale
RT, Rasch transformed; mISS, modiﬁed INCAT sensory sumscore; R-ODS, R
score; FSS, fatigue severity scale; 5-PGIC, 5-points patient global impression o
quality of life.7.3.1. Minimum core set for future MMN studies
 At the impairment level, the Vigorimeter should be used.
In addition, patient-speciﬁc aﬀected muscles should be
incorporated and future studies are needed to
re-determine these patient-speciﬁc MRC sum scores
that may vary from patient to patient. The use of
RT-MRC scores was proposed.
 At the activity and participation level, the RODS-MMN
was suggested.
 At the quality of life level, a Rasch-transformed
outcome measure based on the future ﬁndings of the
PeriNomS study.7.3.2. Future needs in MMN
TheR-ODS could be expanded, possibly using the ALDS
[27] or the ABILHAND [14]. At the quality of life level, a
Rasch-transformed outcome measure based on the future
ﬁndings of the PeriNomS study should be included.
7.4. MGUSP
7.4.1. Recommended outcome measures for future MGUSP
studies
Changes were hardly captured in MGUSP patients.
Since most patients have not received any therapy, theMMN MGUSP
ter Martin Vigorimeter Not yet deﬁned; further study
requiredPatient-speciﬁc muscle
testing
esting’ RT-MRC scores
R-ODS MMN See above
disability
RT-QoL scale See above
– RT-mISS
– R-ODS
Original INCAT 10-point
– PGIC
SF36 or Euro-QoL
– Deﬁne core set
Pain
Ataxia
Tremor
9-hole PEG test
ODS Expanding the R-ODS Deﬁne core set
RT-QoL scale RT-QoL scale
asch-built overall disability scale; MRCss, Medical Research Council sum
f change; 11-PI-NRS, 11-point pain-intensity numerical rating scale; QoL,
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Therefore, a core set could not be deﬁned. The group
agreed upon extending the evaluation of patients with
MGUSP over a much longer period. In addition, more
data on a larger sample size receiving therapy is needed
before a minimum core set of outcome measures for
future trials can be deﬁned.
However, at this point, the RT-mISS was recommended
at the impairment level, and the R-ODS was recommended
at the activity and participation level (the latter as primary
outcome suggested). Also the original INCAT 10-point
disability should be included based on signiﬁcant p-values
seen in two previous trials [35] (1 not published yet). At
the quality of life level, the PGIC and the SF-36 or
Euro-QoL were arbitrarily recommended.
7.4.2. Future needs in MGUSP
Extending the evaluation of patients with MGUSP over
a longer period is needed. More treated patients should
also be examined. At the impairment level, pain
evaluation, ataxia and a tremor score as well as the 9-
hole PEG test could be further explored. At the quality
of life level, a Rasch-transformed outcome measure based
on the future ﬁndings of the PeriNomS study should be
included.
8. Overall and closure
Consensus was reached for most illnesses at the various
levels of assessing outcome, except regarding whether there
is a need to perform manual muscle testing and how to
handle the data. The Rasch-built activity and
participation measures were proposed as the future
primary outcome measures in all illnesses.
Recommendations were made for additional evaluation
of aspects like fatigue, pain, and mobility, and future
needs were systematically highlighted. Additional
evaluation in MGUSP over a longer period of time,
particularly in patients receiving therapy was also agreed
upon. The PeriNomS group will also be focusing on
determining the impact of collected skin biopsy data as
well as the construction of an inﬂammatory neuropathy
speciﬁc Rasch-built quality of life metric.
Last but not least, the PeriNomS study is performing
more than collecting and evaluating data in inﬂammatory
neuropathies. The PeriNomS contributes to the wrinkles
needed to create a paradigm shift in outcome assessment
in future peripheral neuropathic studies and could serve
as an example for other illnesses in neurology and
medicine in general.
9. Participants (all members of the PeriNomS study group
except*)
Prof. P. Van den Bergh, Brussels, Belgium,
Prof. V. Bril, Toronto, Canada,
Prof. P.A. van Doorn, Rotterdam, The Netherlands,Dr. C.G. Faber, Maastricht, The Netherlands,
Prof. K. Gorson, Boston, USA,
Prof. A. Hahn, London, Canada,
Prof. R.A.C. Hughes, London, UK,
Dr. A. van der Kooi, Amsterdam, The Netherlands,
Dr. G. Lauria, Milan, Italy,
Prof. J-M Leger, Paris, France,
Prof. R. Lewis, LA, USA,
Dr. M. Lunn, London, UK,
Dr. I.S.J. Merkies, Hoofddorp and Maastricht, The
Netherlands,
Prof. E. Nobile-Orazio, Milan, Italy,
Dr. N.C. Notermans, Utrecht, The Netherlands,
Dr. L. Querol, Barcelona, Spain,
*Mrs. G. Sanders MBE, Lincolnshire, UK,
Prof. I. van Schaik, Amsterdam, The Netherlands,
Drs. E. Vanhoutte, Maastricht, The Netherlands.
From ENMC:
Daniel Zollinger, Research Manager,
Annelies Zitterstein, Management Assistant, and
Professor Baziel van Engelen, Research Director.
Members of the PeriNomS study group, not present:
Dr. A.A. Barreira, Brazil; Dr. D. Bennett, UK; Prof.
L.H. van den Berg, The Netherlands; Prof. D.R.
Cornblath, USA; Dr. G. Devigili, Italy; Dr. R.D.
Hadden, UK; UK; Prof. I. Illa, Spain; Dr. L. Padua,
Italy; Prof. J. Pouget, France; Prof. Dr. M.M. Reilly,
UK; Prof M. de Visser, The Netherlands; Dr. S.I. van
Nes, The Netherlands; Prof. Dr. D. Walk, USA.Acknowledgements
This workshop was made possible thanks to the
ﬁnancial support of ZONMw, the European
Neuromuscular Centre (ENMC) and ENMC main
sponsors: Association Francaise contre les Myopathies
(France), Deutsche Gesellschaft fu¨r Muskelkranke
(Germany), Telethon Foundation (Italy), Muscular
Dystrophy Campaign (UK), Muskelvindfonden
(Denmark), Prinses Beatrix Spierfonds (The
Netherlands), Schweizerische Stiftung fu¨r die Erforschung
der Muskelkrankheiten (Switzerland), Spierziekten
Nederland (The Netherlands), and associated members:
Finnish Neuromuscular Association (Finland).References
[1] Merkies IS, Lauria G. 131st ENMC international workshop:
selection of outcome measures for peripheral neuropathy clinical
trials 10–12 December 2004, Naarden, The Netherlands.
Neuromuscul Disord 2006;16(2):149–56.
[2] van Nes SI, Vanhoutte EK, van Doorn PA, et al.. Rasch-built overall
disability scale (R-ODS) for immune-mediated peripheral
neuropathies. Neurology 2011;76(4):337–45.
[3] van Nes SI, Faber CG, Merkies IS. Outcome measures in immune-
mediated neuropathies: the need to standardize their use and to
understand the clinimetric essentials. J Peripher Nerv Syst
2008;13(2):136–47.
E.K. Vanhoutte et al. / Neuromuscular Disorders 23 (2013) 924–933 933[4] Dyck PJ, Boes CJ, Mulder D, et al.. History of standard scoring,
notation, and summation of neuromuscular signs. A current survey
and recommendation. J Peripher Nerv Syst 2005;10(2):158–73.
[5] Kleyweg RP, van derMeche FG, Schmitz PI. Interobserver agreement
in the assessment of muscle strength and functional abilities in
Guillain–Barre syndrome. Muscle Nerve 1991;14(11):1103–9.
[6] Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA.
Psychometric evaluation of a new sensory scale in immune-mediated
polyneuropathies. Inﬂammatory Neuropathy Cause and Treatment
(INCAT) Group. Neurology 2000;54(4):943–9.
[7] Streiner DL, Norman GR. Health measurement scales: a practical
guide to their development and use. 2nd ed. (NY) USA: Oxford
University Press; 1998.
[8] Latov N, Deng C, Dalakas MC, et al.. Timing and course of clinical
response to intravenous immunoglobulin in chronic inﬂammatory
demyelinating polyradiculoneuropathy. Arch Neurol
2010;67(7):802–7.
[9] DeVellis RF. Classical test theory. Med Care 2006;44(11 Suppl.
3):S50–9.
[10] World Health Organisation. The international classiﬁcation of
functioning, disability and health (ICF). WHO; 2001.
[11] Tennant A, Conaghan PG. The Rasch measurement model in
rheumatology: what is it and why use it? When should it be
applied, and what should one look for in a Rasch paper? Arthritis
Rheum 2007;57(8):1358–62.
[12] Rasch G. Probabilistic models for some intelligence and attainment
tests. Copenhagen: University of Chicago Press; 1960.
[13] Vandervelde L, Van den Bergh PY, Goemans N, Thonnard JL.
ACTIVLIM: a Rasch-built measure of activity limitations in children
and adults with neuromuscular disorders. Neuromuscul Disord
2007;17(6):459–69.
[14] Wang TN, Lin KC, Wu CY, Chung CY, Pei YC, Teng YK. Validity,
responsiveness, and clinically important diﬀerence of the
ABILHAND questionnaire in patients with stroke. Arch Phys Med
Rehabil 2011;92(7):1086–91.
[15] Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically
important diﬀerence (MCID): a literature review and directions for
future research. Curr Opin Rheumatol 2002;14(2):109–14.
[16] Jaeschke R, Singer J, Guyatt GH. Measurement of health status.
Ascertaining the minimal clinically important diﬀerence. Control Clin
Trials 1989;10(4):407–15.
[17] Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Conﬁrming
the eﬃcacy of intravenous immunoglobulin in CIDP through
minimum clinically important diﬀerences: shifting from statistical
signiﬁcance to clinical relevance. J Neurol Neurosurg Psychiatry
2010;81(11):1194–9.
[18] Hobart J, Cano S. Improving the evaluation of therapeutic
interventions in multiple sclerosis: the role of new psychometric
methods. Health Technol Assess 2009;13(12), p. iii, ix–x, 1–177.
[19] Wright BD, Stone MH. Best test design. Chicago: Mesa Press; 1979.
[20] Vanhoutte EK, Faber CG, van Nes SI, et al.. Modifying the Medical
Research Council grading system through Rasch analyses. Brain
2012;135(Pt 5):1639–49.[21] van Nes SI, Faber CG, Hamers RM, et al.. Revising two-point
discrimination assessment in normal aging and in patients with
polyneuropathies. J Neurol Neurosurg Psychiatry 2008;79(7):832–4.
[22] Lauria G, Bakkers M, Schmitz C, et al.. Intraepidermal nerve ﬁber
density at the distal leg: a worldwide normative reference study. J
Peripher Nerv Syst 2010;15(3):202–7.
[23] Ruts L, van Doorn PA, Lombardi R, et al.. Unmyelinated and
myelinated skin nerve damage in Guillain-Barre syndrome:
correlation with pain and recovery. Pain 2012;153(2):399–409.
[24] Lauria G, Cazzato D, Porretta-Serapiglia C, et al.. Morphometry of
dermal nerve ﬁbers in human skin. Neurology 2011;77(3):242–9.
[25] Bril V, Banach M, Dalakas MC, et al.. Electrophysiologic
correlations with clinical outcomes in CIDP. Muscle Nerve
2010;42(4):492–7.
[26] Querol L, Nogales-Gadea G, Rojas-Garcia R, et al.. Antibodies to
contactin-1 in chronic inﬂammatory demyelinating polyneuropathy.
Annals of neurology 2013;73(3):370–80.
[27] Holman R, Lindeboom R, Vermeulen M, de Haan RJ. The AMC
Linear Disability Score project in a population requiring residential
care: psychometric properties. Health Qual Life Outcomes 2004;2:
42.
[28] Holman R, Weisscher N, Glas CA, et al.. The Academic Medical
Center Linear Disability Score (ALDS) item bank: item response
theory analysis in a mixed patient population. Health Qual Life
Outcomes 2005;3:83.
[29] Hughes R, Bensa S, Willison H, et al.. Randomized controlled trial of
intravenous immunoglobulin versus oral prednisolone in chronic
inﬂammatory demyelinating polyradiculoneuropathy. Ann Neurol
2001;50(2):195–201.
[30] Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann
N. Intravenous immunoglobulin therapy in multifocal motor
neuropathy: a double-blind, placebo-controlled study. Brain
2001;124(Pt 1):145–53.
[31] van Nes SI, Vanhoutte EK, Faber CG, Garssen M, van Doorn PA,
Merkies IS. Improving fatigue assessment in immune-mediated
neuropathies: the modiﬁed Rasch-built fatigue severity scale. J
Peripher Nerv Syst 2009;14(4):268–78.
[32] Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM.
Clinical importance of changes in chronic pain intensity measured on
an 11-point numerical pain rating scale. Pain 2001;94(2):149–58.
[33] Ware Jr JE, Kosinski M, Gandek B. SF-36 Health Survey. Manual
and interpretation guide. Lincoln (RI): QualityMetric Incorporated;
2000.
[34] Vanhoutte EK, van Nes SI, Cats EA, et al.. Rasch-Built overall
disability scale for multifocal motor neuropathy (RODS-MMN).
Abstracts of the 2011 Meeting of the Peripheral Nerve Society. June
25–29, 2011. Potomac, Maryland, USA. J Peripher Nerv Syst
2011;16(Suppl 3):S1–174.
[35] Dalakas MC, Rakocevic G, Salajegheh M, et al.. Placebo-controlled
trial of rituximab in IgM anti-myelin-associated glycoprotein
antibody demyelinating neuropathy. Annals of neurology
2009;65(3):286–93.
